Glutamine metabolism affects T cell signaling and function

November 01, 2018

The cellular nutrient glutamine launches a metabolic signaling pathway that promotes the function of some immune system T cells and suppresses others, Vanderbilt researchers have discovered.

They show that a drug that inhibits glutamine metabolism -- currently in clinical trials as an anticancer agent -- might also be useful as a treatment for inflammatory and autoimmune diseases. The study, published online this week in the journal Cell, also suggests strategies for using the drug to enhance cancer immunotherapies.

Jeffrey Rathmell, PhD, Cornelius Vanderbilt Professor of Immunobiology, and his colleagues have focused on trying to understand how a cell integrates its nutrients and metabolism with its function. They previously demonstrated the importance of the cellular fuel glucose for the activation and function of T cells that drive inflammation and eliminate pathogens.

In the current work, they turned their attention to another major fuel: glutamine, which has primarily been studied in the context of cancer cell metabolism. Several companies are developing drugs that inhibit glutamine metabolism to reduce cancer cell growth and proliferation.

The investigators expected that inhibiting glutamine metabolism -- like blocking glucose metabolism -- would prevent T cell activation and function. They used a drug that inhibits the first step in glutamine metabolism, an enzyme called glutaminase. They also studied mice with targeted genetic deletion of the glutaminase gene.

The researchers were surprised to find that certain T cells -- those that mediate antiviral and anticancer responses -- performed better in the absence of glutaminase activity. Other T cells involved in inflammatory and autoimmune diseases performed worse.

"We were intrigued that one metabolic perturbation could have a very different impact on the function of subsets of T cells," said Marc Johnson, a graduate student who led the studies.

The findings fit with studies of glutamine metabolism in cancer cells, said Rathmell, who is also professor of Pathology, Microbiology and Immunology.

"This compound (that inhibits glutaminase) works in some tumors and doesn't work in others. What Marc found is that it's the same for T cells: some T cells need this pathway, and some don't," Rathmell said. "If we block the pathway, the autoimmune T cells don't do so well, but the anticancer T cells do better."

The researchers demonstrated in mouse models of allergic asthma, inflammatory bowel disease, and chronic graft-versus-host disease that eliminating glutaminase activity protected against inflammation and disease.

"The glutaminase inhibitor has a remarkable safety profile, and we think it could be repurposed in potentially quite a variety of inflammatory and autoimmune diseases," Rathmell said.

To examine the impact of inhibiting glutaminase on T cells that mediate anticancer responses, the investigators used the drug in a mouse model of CAR (chimeric antigen receptor) T-cell therapy. CAR T cells are cancer-killing T cells that have been genetically engineered to recognize specific cancer cells.

In the mouse model, the researchers found that treatment with the glutaminase inhibitor improved CAR T-cell function, but the enhanced function was lost over time. A shorter exposure to the inhibitor improved CAR T-cell function, and the T cells persisted for a longer period of time.

"One of the problems with CAR T-cell therapy is survival of the engineered cells," Johnson said. "We think that a short treatment with a glutaminase inhibitor might improve the persistence of CAR T cells."

The findings have implications for current clinical trials of a glutaminase inhibitor in combination with immunotherapies called checkpoint inhibitors, Rathmell said.

"Our data suggest that the combination of drugs might work best if you give the glutaminase inhibitor for a short period of time and then remove it."

The investigators are testing varied dosing schedules in mouse models of cancer.

The researchers also probed the mechanistic changes resulting from glutaminase inhibition and demonstrated that the glutamine metabolic pathway -- usually thought of as only generating energy -- is tightly integrated with cell signaling and gene expression.

"By changing this metabolic enzyme, we're affecting a downstream metabolite that directly changes chromatin and gene accessibility and gene expression," Rathmell said. "As a concept, this idea that metabolic pathways are signaling pathways is relatively new."
This research was supported by grants from the National Institutes of Health (HL136664, DK105550, CA217987, CA193256, CA001423). Calithera Biosciences provided some of the glutaminase inhibitor for in vitro studies.

Vanderbilt University Medical Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to